PI3K/AKT inhibitor BEZ-235 targets CCND2 and induces G1 arrest in breast implant-associated anaplastic large cell lymphoma.

[1]  H. Quentmeier,et al.  Genomic Aberrations Generate Fusion Gene FOXK2::TP63 and Activate NFKB1 in Cutaneous T-Cell Lymphoma , 2022, Biomedicines.

[2]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[3]  C. Pommerenke,et al.  DSMZCellDive: Diving into high-throughput cell line data , 2022, F1000Research.

[4]  R. Geffers,et al.  Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma , 2022, Scientific Reports.

[5]  A. Deva,et al.  What are the likely causes of breast implant associated anaplastic large cell lymphoma (BIA-ALCL)? , 2022, JPRAS open.

[6]  Marilyn M. Li,et al.  Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia , 2021, Haematologica.

[7]  C. Uphoff,et al.  Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies , 2021, PloS one.

[8]  M. Copland,et al.  The application of BH3 mimetics in myeloid leukemias , 2021, Cell Death and Disease.

[9]  R. Thijssen,et al.  BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic , 2020, Cancers.

[10]  Verena Wagner,et al.  Senescence as a therapeutically relevant response to CDK4/6 inhibitors , 2020, Oncogene.

[11]  G. Inghirami,et al.  Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant–Associated Anaplastic Large-Cell Lymphoma , 2020, The American journal of pathology.

[12]  Yu Cao,et al.  CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263 , 2019, Cell Death & Disease.

[13]  H. Drexler,et al.  The LL-100 panel: 100 cell lines for blood cancer studies , 2019, Scientific Reports.

[14]  M. Kadin.  What Cytokines Can Tell Us About the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). , 2019, Aesthetic surgery journal.

[15]  A. Valencia,et al.  DNA methylation profiling of hepatosplenic T-cell lymphoma , 2018, Haematologica.

[16]  L. Medeiros,et al.  Breast implant-associated anaplastic large cell lymphoma: a review , 2018, Modern Pathology.

[17]  T. Waldmann,et al.  Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations , 2017, Proceedings of the National Academy of Sciences.

[18]  Daniel J. Weisenberger,et al.  Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling , 2016, Cell reports.

[19]  Jie Jin,et al.  The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features , 2016, PloS one.

[20]  R. Roskoski.  Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. , 2016, Pharmacological research.

[21]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[22]  M. Toribio,et al.  Regulation of the transcriptional program by DNA methylation during human αβ T-cell development , 2014, Nucleic acids research.

[23]  Martin J. Aryee,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[24]  Xiaomei Ma,et al.  A global DNA methylation and gene expression analysis of early human B-cell development reveals a demethylation signature and transcription factor network , 2012, Nucleic acids research.

[25]  A. Epstein,et al.  Survival Signals and Targets for Therapy in Breast Implant–Associated ALK− Anaplastic Large Cell Lymphoma , 2012, Clinical Cancer Research.

[26]  B. Falini,et al.  Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy , 2009, Haematologica.

[27]  H. Drexler,et al.  SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines , 2009, Journal of hematology & oncology.

[28]  C. Proud,et al.  Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1 , 2008, Oncogene.

[29]  S. Kotani,et al.  Glycogen synthase kinase-3β and p38 phosphorylate cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent degradation in hematopoietic cells , 2007, Oncogene.

[30]  R. Siebert,et al.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. , 2006, The Journal of molecular diagnostics : JMD.

[31]  L. Staudt,et al.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. , 2005, Blood.

[32]  R. Siebert,et al.  Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci , 2003, Leukemia.

[33]  D. Johnson,et al.  Cyclins and cell cycle checkpoints. , 1999, Annual review of pharmacology and toxicology.

[34]  M. Höglund,et al.  Genomic amplification of CCND2 is rare in non-Hodgkin lymphomas. , 1998, Cancer genetics and cytogenetics.

[35]  Sibylle Mittnacht,et al.  Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases* , 1997, The Journal of Biological Chemistry.

[36]  S. Moreno,et al.  Regulation of CDK/cyclin complexes during the cell cycle. , 1997, The international journal of biochemistry & cell biology.

[37]  E. Harlow,et al.  Identification of G1 kinase activity for cdk6, a novel cyclin D partner , 1994, Molecular and cellular biology.

[38]  Tai Wang,et al.  Migratory localization of cyclin D2-Cdk4 complex suggests a spatial regulation of the G1-S transition. , 2008, Cell structure and function.

[39]  F. Sigaux,et al.  Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias , 2006, Leukemia.